Journal Article

FZJ-2022-02209

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization

Bhatia, S. (Corresponding author) ; Spanier, L. ; Bickel, D. ; Dienstbier, N. ; Woloschin, V. ; Vogt, M. ; Pols, H. ; Lungerich, B. ; Reiners, J. ; Aghaallaei, N. ; Diedrich, D. ; Frieg, B.FZJ* ; Schliehe-Diecks, J. ; Bopp, B. ; Lang, F. ; Gopalswamy, M.FZJ* ; Loschwitz, J.FZJ* ; Bajohgli, B. ; Skokowa, J. ; Borkhardt, A. ; Hauer, J. ; Hansen, F. K. ; Smits, S. H. J. ; Jose, J. ; Gohlke, H. (Corresponding author)FZJ* ; Kurz, T. (Corresponding author)

2022
ACS Publ. Washington, DC

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/31238  doi:10.1021/acscentsci.2c00013

Abstract: Heat shock proteins 90 (Hsp90) are promising therapeutic targets due to their involvement in stabilizing several aberrantly expressed oncoproteins. In cancerous cells, Hsp90 expression is elevated, thereby exerting antiapoptotic effects, which is essential for the malignant transformation and tumor progression. Most of the Hsp90 inhibitors (Hsp90i) under investigation target the ATP binding site in the N-terminal domain of Hsp90. However, adverse effects, including induction of the prosurvival resistance mechanism (heat shock response or HSR) and associated dose-limiting toxicity, have so far precluded their clinical approval. In contrast, modulators that interfere with the C-terminal domain (CTD) of Hsp90 do not inflict HSR. Since the CTD dimerization of Hsp90 is essential for its chaperone activity, interfering with the dimerization process by small-molecule protein–protein interaction inhibitors is a promising strategy for anticancer drug research. We have developed a first-in-class small-molecule inhibitor (5b) targeting the Hsp90 CTD dimerization interface, based on a tripyrimidonamide scaffold through structure-based molecular design, chemical synthesis, binding mode model prediction, assessment of the biochemical affinity, and efficacy against therapy-resistant leukemia cells. 5b reduces xenotransplantation of leukemia cells in zebrafish models and induces apoptosis in BCR-ABL1+ (T315I) tyrosine kinase inhibitor-resistant leukemia cells, without inducing HSR.

---

Contributing Institute(s):

1. Bioinformatik (IBG-4)
2. Jülich Supercomputing Center (JSC)
3. John von Neumann - Institut für Computing (NIC)
4. Strukturbiochemie (IBI-7)

Research Program(s):

1. 5111 - Domain-Specific Simulation & Data Life Cycle Labs (SDLs) and Research Groups (POF4-511) (POF4-511)
2. 2171 - Biological and environmental resources for sustainable use (POF4-217) (POF4-217)
3. Forschergruppe Gohlke (hkf7_20200501) (hkf7_20200501)
4. 5241 - Molecular Information Processing in Cellular Systems (POF4-524) (POF4-524)

Appears in the scientific report 2022

---

Database coverage:
; ; ; ; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Essential Science Indicators ; IF >= 15 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---